Information  X 
Enter a valid email address

Santander UK Plc (65WK)

  Print   

Friday 21 January, 2022

Santander UK Plc

Article 17 notification - Issue 1197

RNS Number : 2713Z
Santander UK Plc
21 January 2022
 

ARTICLE 17 NOTIFICATION

 

Santander UK plc (the "Issuer")

 

 

This notification refers to:

 

(1)  the Base Prospectus dated 19 March 2021, as supplemented from time to time (the Base Prospectus) for Notes to be issued by the Issuer under its Structured Note and Certificate Programme; and

 

(2)  the Final Terms dated 8 November 2021   (the Final Terms) in respect of the issue of up to £20,000,000 Preference Share-linked Autocallable Notes due 2028 - Series 1197 (XS2403524197) (the Note Issue).

 

Pursuant to our obligations under Article 17 of the Prospectus Regulation (Regulation 2017/1129/EU, as amended and as incorporated into the law of the United Kingdom by the European Union (Withdrawal) Act 2018, as amended) we confirm in respect of the Note Issue the following information:

 

Final Aggregate Nominal Amount:  £426,857

 

Paragraphs 4.1 and 4.2 of Part A to the Final Terms shall be read accordingly.

 

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the Base Prospectus and the Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus and/or the Final Terms) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus and/or the Final Terms is not addressed. Prior to relying on the information contained in the Base Prospectus and/or the Final Terms, you must ascertain from the Base Prospectus and/or the Final Terms whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirement.

Neither the Base Prospectus nor the Final Terms referenced herein constitute an offer of securities for sale in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America, and may not be offered or sold to U.S. persons or to persons within the United States of America, except pursuant to an exemption from the Securities Act.

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCSEIFDFEESEEF

a d v e r t i s e m e n t